Deyaa Adib, MD, on Targeting HER2 in Solid Tumors With the TAC Platform
The chief medical officer of Triumvira Immunologics discussed promising early results from the company’s phase 1/2 clinical trial.
Peter Bross, MD, on the Importance of Transparency and Communication With the FDA
The chief of the oncology branch of the Center for Biologics Evaluation and Research at the FDA discussed how academia and industry can work best with regulatory agencies.
Deyaa Adib, MD, on Using T-Cell Antigen Coupler Technology to Target Solid Tumors
The chief medical officer of Triumvira Immunologics discussed the company’s TAC platform and its versatile target-recognizing domain.
Pursuing Strategic Partnerships in Cell Therapy
Raphaël G. Ognar, chief executive officer and co-founder of NKILT Therapeutics, discussed approaches to help increase patient access to cell therapies.
Geoffrey Hodge on Developing CAR T-Cell Therapies for Solid Tumors
Geoffrey Hodge, chief executive officer of SOTIO Biotech US, discussed the company's development of the BOXR cell therapy platform.
Alba Gonzalez-Junca, PhD, on Logic-gated CAR-NK Cell Development
The associate director of Research at Senti Biosciences discussed the company's research on using logic-gated CAR-NK cells for the treatment of AML and solid tumors.
Gavin Macbeath, PhD, on Screening for Off-Target Effects
The chief scientific officer at TScan Therapeutics discussed the company’s SafetyScan technology.
Michael Leek, PhD, on Manufacturing Challenges in Cell Therapy
The co-founder and executive chairman of TC BioPharm discussed his thoughts on the regulatory, logistical, and quality hurdles of manufacturing cell therapies.
Serena De Vita, MD, PhD, on Speedy Manufacturing of PHE885 for Multiple Myeloma
The senior director and clinical program leader, Translational Clinical Oncology at Novartis Institutes for BioMedical Research, discussed new data from the phase 1 study.
Jeffrey Miller, MD, on Improving NK Cells for Solid and Hematologic Malignancies
The professor of medicine and University of Minnesota Medical School discussed the advantages and unmet needs of natural killer cells in oncology.
Stefanie Bailey, PhD, on the Role of Interferon-γ in CAR T-Cell Therapy
The research fellow from Harvard Medical School discussed blocking IFNg as a potential approach to reduce toxicities.
Adham Bear, MD, On Immunotherapy Targeting Mutant KRAS
The instructor of Medicine, Division of Hematology and Oncology, Hospital of the University of Pennsylvania discussed his thoughts on the potential of targeting mutant KRAS with immunotherapy.
Christian Hinrichs, MD, on Improving Solid Tumor Targeting With Engineered T-Cell Therapies
The chief of cancer immunotherapy at Rutgers Cancer Institute discussed clinical results with different cell therapy approaches.
Breanna DiAndreth, PhD, on Improving Selective Targeting of Tumor Cells
The scientist at A2 Biotherapeutics discussed the company’s dual-receptor Tmod technology.
Peter Bross, MD, on Regulating Cell Therapies: Lessons Learned
The acting chief of the oncology branch of the Center for Biologics Evaluation and Research at the FDA discussed the evolution of cell therapies in the past decade.
